logo
  

Shire Considers Bid For NPS Pharma : Report

Irish drug company Shire Plc (SHP.L, SHPG) is considering a bid for NPS Pharmaceuticals Inc. (NPSP), Bloomberg reported citing people familiar with the matter said.

Quoting two of the people, the report said that the timing of any offer could depend on whether the U.S. Food and Drug Administration approves NPS's Natpara, a drug to treat hypoparathyroidism that if authorized would be the first marketed treatment for the potentially fatal disorder. The decision is scheduled to happen by January 24.

Separately, Shire disclosed in a regulatory that it agreed on a $2.1 billion revolving loan facility from a number of financial institutions. The revolving facility may be applied towards financing the general corporate purposes of the company.

SHPG closed Wednesday's regular trading at $215.25, up $6.49 or 3.11%. In after-hours, the share further gained $0.06 or 0.03%.

NPSP closed regular trading at $36.10, up $5.63 or 18.48%. In after-hours, the share further gained $0.10.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Rancho Cordova, California-based E-filliate Inc. is recalling about 301,800 units of DEWALT wireless earphones citing burn and fire risks, the U.S. Consumer Product Safety Commission said. The recall involves DEWALT Jobsite Pro Wireless Earphones, which have a black and yellow neckband with wired earbuds. According to the agency, the wireless earphones can overheat while charging or in use. The five-day holiday shopping period from Thanksgiving Day through Cyber Monday saw about 180 million Americans making in-store and online purchases, according to the National Retail Federation's Annual Thanksgiving Weekend Consumer Survey, conducted by Prosper Insights & Analytics. The shoppers spent an average of $301.27 on holiday-related purchases such as gifts, décor, apparel and toys. Biopharmaceutical company Immunome, Inc. (IMNM) announced Wednesday that it has conducted an assessment of the reported mutations in the new SARS-CoV-2 variant, Omicron (B.1.1.529). Based upon structural mapping of those mutations and activity against previous and current CDC variants of concern,...
Follow RTT